Key result
This review summarizes the clinical use, safety, and efficacy of new oral anticoagulants as alternatives to warfarin for the prevention and treatment of venous thromboembolic disease.
Why the study?
Do new oral anticoagulants (NOACs) provide safe and effective alternatives to warfarin for the prevention and treatment of venous thromboembolic (VTE) disease?
Do new oral anticoagulants (NOACs) provide safe and effective alternatives to warfarin for the prevention and treatment of venous thromboembolic (VTE) disease?
Answers are grounded in this paper and cite their sources.
This review summarizes the clinical use and landmark trials of NOACs as alternatives to warfarin for VTE management.
New oral anticoagulants (NOAC) serve as alternatives for patients currently using warfarin for the prevention and treatment of venous thromboembolic (VTE) disease. This article provides a brief summary of the clinical use of these drugs as well as a review of the landmark clinical trials which evaluated described their safety and efficacy. As more data becomes available, a fundamental understanding of these medications will be vital to cardiovascular practitioners managing patients with VTE.
No takes yet. Share an insight, caveat, or question.
Madan et al. (2016) conducted a review in Venous thromboembolic (VTE) disease. New oral anticoagulants (NOAC) vs. Warfarin was evaluated. This review summarizes the clinical use, safety, and efficacy of new oral anticoagulants as alternatives to warfarin for the prevention and treatment of venous thromboembolic disease.
Synapse has enriched 10 related papers. Consider them for comparative context: